scholarly journals Relapse episodes in childhood primary nephrotic syndrome treated by alternate or three consecutive daily dose prednisone therapy

2016 ◽  
Vol 48 (6) ◽  
pp. 338
Author(s):  
Denny Sujatno ◽  
M. P. Damanik ◽  
Purnomo Suryantoro
Keyword(s):  
Nephrotic Syndrome ◽  
Cohort Study ◽  
Retrospective Cohort ◽  
Dose Group ◽  
Primary Nephrotic Syndrome ◽  
Prednisone Therapy ◽  
Drug Of Choice ◽  
Daily Dose ◽  
Consecutive Dose ◽  
Dose Prednisone

Background Prednison is still the drug of choice for the treatmentof nephrotic syndrome, especially for those with minimal change.Methods of treatment to optimize the effectiveness and efficacyare still in discussion.Objectives To evaluate the episode of relapsing minimal changenephrotic syndrome patients who received prednisone therapy byalternate or by three consecutive dose methods.Methods We performed a retrospective cohort study using medicalrecords of the patients with primary nephrotic syndrome admittedto Division of Nephrology, Sardjito Hospital, Yogyakarta fromJanuary 1995 to January 2005. Subjects were divided into twogroups, the first group treated with alternate days while thesecond group with three consecutive days prednisone program.Evaluation had been done to compare both treatment program(alternate days or consecutive days).Results Relapse episodes after six month recovery periods withalternate days treatment was 33% while those with consecutivedays was as high as 83% (P>O.Ol).Conclusion Alternate dose group has a lower relapse eventcompared to three consecutive dose group in children withnephrotic syndrome.

Daily dose of clindamycin versus standard divided doses in obstetrical and gynecological infections: a retrospective cohort study

2013 ◽  
Vol 24 (11) ◽  
pp. 893-898 ◽  
Author(s):  
Cláudia S Giugno ◽  
Alice L Silva ◽  
Daniele G Fuhrich ◽  
Paola S Rabaioli ◽  
Katia G Gonçalves ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Daily Dose ◽  
Gynecological Infections

Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon

2003 ◽  
Vol 90 (08) ◽  
pp. 260-266 ◽  
Author(s):  
Alain Gadisseur ◽  
Edwin Pasterkamp ◽  
Felix van der Meer ◽  
W. G. Mimi Breukink-Engbers ◽  
Lya Geven-Boere ◽  
...  
Keyword(s):  
Cohort Study ◽  
Anticoagulant Therapy ◽  
Therapeutic Range ◽  
Oral Anticoagulant ◽  
Retrospective Cohort ◽  
Oral Anticoagulant Therapy ◽  
Drug Of Choice ◽  
Anticoagulation Clinics ◽  
International Normalised Ratio ◽  
Regional Anticoagulation

SummaryVariability in the control of oral anticoagulant therapy has been associated with a heightened risk of complications. We compared control of anticoagulation between two commonly used coumarins, phenprocoumon and acenocoumarol, and among anticoagulation clinics.All qualifying patients were managed at six regional anticoagulation clinics in the Netherlands.This retrospective cohort study compiled data during a three-year period from a computerised dosing and management system. Anticoagulation control was expressed as the percent of time within the therapeutic range and stability expressed as the time-weighted variance in the international normalised ratio (INR). Data were available for 22,178 patients of whom 72% were treated with acenocoumarol. INRs of patients who received phenprocoumon were within the therapeutic range 50% of the time compared with 43% for acenocoumarol (OR 1.32,95% CI 1.24-1.41). Moreover, patients on phenprocoumon required 15% fewer monitoring visits and had more stable INR values. These observations were consistent for all six clinics. There were also sizable differences between the clinics with respect to control and stability of anticoagulation that were stable from year-to-year and were unrelated to the drug used.With its longer half-life of three to five days, phenprocoumon produces more stable anticoagulation than acenocoumarol and should generally be the drug of choice when these are the available choices. The differences observed among clinics suggest that certain clinics employ policies and practices resulting in better control of anticoagulation.

Single daily dose prednisone therapy

JAMA ◽  
1979 ◽  
Vol 241 (25) ◽  
pp. 2721-2723 ◽  
Author(s):  
H. F. Klinefelter
Keyword(s):  
Single Daily Dose ◽  
Prednisone Therapy ◽  
Daily Dose ◽  
Dose Prednisone

Risk factors of venous thromboembolism in patients with nephrotic syndrome: a retrospective cohort study

2020 ◽  
Author(s):  
Kanna Shinkawa ◽  
Satomi Yoshida ◽  
Tomotsugu Seki ◽  
Motoko Yanagita ◽  
Koji Kawakami
Keyword(s):  
Risk Factors ◽  
Nephrotic Syndrome ◽  
Cohort Study ◽  
Venous Thromboembolism ◽  
Lupus Nephritis ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Vein Thrombosis ◽  
Female Sex ◽  
Increased Risk

Abstract Background Nephrotic syndrome is associated with an increased risk of venous thromboembolism (VTE). However, the risk factors of VTE in nephrotic syndrome, other than hypoalbuminemia and severe proteinuria, are not well established. Therefore we aimed to investigate the risk factors of VTE in patients with nephrotic syndrome. Methods This retrospective cohort study used data from a Japanese nationwide claims database. We identified patients ≥18 years of age hospitalized with nephrotic syndrome. Through multivariable logistic regression, we determined the risk factors of VTE in patients with nephrotic syndrome during hospitalization. Results Of the 7473 hospitalized patients with nephrotic syndrome without VTE, 221 (3.0%) developed VTE. In the VTE group, 14 (6.3%), 11 (5.0%) and 198 (89.6%) patients developed pulmonary embolism, renal vein thrombosis and deep vein thrombosis, respectively. We found that female sex {odds ratio [OR] 1.39 [95% confidence interval (CI) 1.05–1.85]}, body mass index (BMI) ≥30 [OR 2.01 (95% CI 1.35–2.99)], acute kidney injury [AKI; OR 1.67 (95% CI 1.07–2.62)], sepsis [OR 2.85 (95% CI 1.37–5.93)], lupus nephritis [OR 3.64 (95% CI 1.58–8.37)] and intravenous corticosteroids use [OR 2.40 (95% CI 1.52–3.80)] were associated with a significantly higher risk of developing VTE. Conclusions In patients with nephrotic syndrome, female sex, BMI ≥30, AKI, sepsis, lupus nephritis and intravenous corticosteroid use may help evaluate the risk of VTE.

scholarly journals Risk of Nephrotic Syndrome following Enteroviral Infection in Children: A Nationwide Retrospective Cohort Study

PLoS ONE ◽  
2016 ◽  
Vol 11 (8) ◽  
pp. e0161004 ◽  
Author(s):  
Jiun-Nong Lin ◽  
Cheng-Li Lin ◽  
Chi-Hui Yang ◽  
Ming-Chia Lin ◽  
Chung-Hsu Lai ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Enteroviral Infection
Sign in / Sign up

Export Citation Format

Share Document